

# Quality Use of Medicine Report **Antipsychotics for behavioural and psychological symptoms of dementia**

Sunshine Gardens Nursing Home (SG)

Date of Report: 12/02/2016

Date Printed: 12/02/2016

## **IMPORTANT NOTICE**

### **COPYRIGHT**

Copyright © National Prescribing Service Limited, Manrex Pty Limited trading as Webstercare ("Author") 2013

This work is copyright. Apart from any use as permitted under the Copyright Act 1968 (C'th), no part may be reproduced by any person or by any process without prior written permission from the Author. All rights are reserved, including the right to reproduce, distribute, cite, publish, store and retrieve, record, communicate to the public, adapt, or perform in whole or in part, in any form or by any means including: electronic, mechanical, written or otherwise, without prior written permission of the Author.


### **DISCLAIMER**

This report has been prepared for health professionals but no warranty, express or implied, is given regarding the accuracy, currency or completeness of the information contained in it. Health professionals must rely on their own expertise and inquiries, taking into account the individual circumstances of each patient when providing medical advice or treatment.

To the extent permitted by law, the Authors are not liable (including as a result of negligence) for any loss, damage or injury resulting from reliance on or use of the information contained in this report. (D:\gpa\pige0.2290Td(C2\_11Tf0Tc4\37sa0003Tf0Tc1.480Tdboi)8.5s90Td(the)Tj\C2\_11Tf0Th







\* Some residents may be using more than one antipsychotic medicine.

† Other atypical antipsychotics include amisulpride, aripiprazole, asenapine, clozapine, olanzapine, paliperidone, quetiapine, sertindole, ziprasidone.

‡ Conventional antipsychotics include chlorpromazine, droperidol, flupenthixol, fluphenazine, haloperidol, pericyazine, trifluoperazine and zuclopenthixol.

## Interpreting Graph 1

Graph 1 shows your RACF antipsychotic use compared with two other drug surveys from the literature. The drug surveys were from a sample of RACFs in Sydney (44 RACFs) and Tasmania (40 RACFs) and do not indicate best practice or a particular target or benchmark. Rather they are an average of the percentage of residents receiving antipsychotics (for all conditions) in each group and are provided as a comparison.

Please note the limitations of this data. The data from the studies includes residents using 'as required' (or PRN) medicines regularly, but it was not possible to include this in your data. Your electronic data in this graph does not show residents prescribed 'as required' medicines as it cannot be determined how frequently these medicines are administered. However, the percentage of residents prescribed 'as required' antipsychotics is in this report to h0/0.2290Td(t)Tj\_C2\_017fi/ta0Tde03Tj/TT01Tf5p

report

Date of Report: 12/02/2016

---


---

---



## Duration of antipsychotic use at your residential aged care facility

Graph 2



### Interpreting Graph 2

Graph 2 shows the length of time residents have been using regular antipsychotics at your RACF (for all conditions). Residents may have been using an antipsychotic for longer than this graph indicates if they were using the medicine before admission, or have been recently re admitted e.g. returned from hospital stay.

A trial discontinuation of antipsychotic treatment is indicated for most residents with behavioural and psychological symptoms of dementia when stable. Symptoms can fluctuate significantly or resolve completely within 12 weeks, as reflected in the high placebo response rates in clinical trials. Studies report that most patients taken off antipsychotic treatment (for behavioural and psychological symptoms) do not show a worsening of behaviour. 13,14

For those residents prescribed an antipsychotic for behavioural and psychological symptoms of dementia review should occur after no more than 12 weeks and the dose reduced and stopped if possible, especially if there is no observable improvement. 8



## What do my results mean?


There may be multiple reasons for your individual facility results. Some possible (but not exhaustive) reasons to get you thinking about your results are listed below.

---

Possible reasons for short term use include:

### Tracking your results and changes over time

Graph 3



### Interpreting Graph 3

Graph 3 shows how your total antipsychotic use is changing over time. Generally the population of a RACF will not be static and you should expect to see some variation in the percentage of residents using antipsychotics. This graph will assist                      assist

## What do my results mean?

There may

---

---

---







Sunshine Gardens Nursing Home (SG)

---

Current	<u>Dose</u>	<u>Duration</u>

---

## Resident List

### Sunshine Gardens Nursing Home (SG)

#### Residents prescribed PRN antipsychotics

Enter from care plan, notes or chart

<u>Antipsychotic(s)*</u>	<u>Dose</u>	<u>Indication</u>	<u>A</u>	<u>B</u>	<u>C</u>
<b>Mary HARRISON</b> Risperidone 0.5mg tablet <i>First Prescribed: 21/06/2011</i>	1 teatime prn	Agitation			
<b>Dorothy O'SULLIVAN</b> Risperidone 0.5mg tablet <i>First Prescribed: 2/09/2013</i>	1 prn	Extreme Agitation			
<b>Roger WYKES</b> Risperidone 0.5mg tablet <i>First Prescribed: 4/12/2014</i>	1 daily prn	Aggression			

SAMPLE

A = Number of doses given in last 4 weeks. Regular use is defined as being administered 4 or more days per week over the four week period. <sup>2</sup>

B = Has the number of doses per week increased over this time? Yes/No

C = Last review date

\* If a change was made to a resident's medicine on the 'date of report' this list will show all antipsychotic medicines that were active on





## Where do we go for more information?

More information about managing behavioural and psychological symptoms of dementia is available through the following:

**Dementia Behaviour Management Advisory Service**

## Appendix One

Antipsychotics available in Australia <sup>15,16</sup>

Generic Name	Trade name(s)	Formulation
amisulpride	Solian, Sulprix	tablet, liquid
aripiprazole	Abilify	tablet
asenapine	Saphris	wafer
chlorpromazine	Largactil	tablet, liquid, short acting injection
clozapine	Clopine, Clozaril	tablet, liquid
droperidol	Droleptan	short acting injection
flupenthixol	Fluanxol Depot	long acting injection*
fluphenazine	Modecate	long acting injection*
haloperidol	Serenace, Haldol Decanoate	tablet, liquid, short acting and long acting injection*
olanzapine	Lanzek, Ozin, Zylap, Zypine, Zyprexa, Zyprexa Relprevv	tablet, wafer, short acting and long acting injection*
paliperidone	Invega, Invega Sustenna	controlled release tablet, long acting injection*
pericyazine	Neulactil	tablet
quetiapine	Delucon, Quetiaccord, Quipine, Sequase, Seronia, Seroquel, Syquet	tablet, controlled release tablet
risperidone	Ozidal, Rispa, Risperdal, Risperdal Consta, Rispericor, Rixadone	tablet, orally disintegrating tablet, liquid, long acting injection*
sertindole	Serdolect	tablet
trifluoperazine	Stelazine	tablet, liquid
ziprasidone	Zelsin 100mg, 200mg, 400mg, 600mg, 800mg, 1000mg, 1200mg, 1400mg, 1600mg, 1800mg, 2000mg, 2200mg, 2400mg, 2600mg, 2800mg, 3000mg, 3200mg, 3400mg, 3600mg, 3800mg, 4000mg, 4200mg, 4400mg, 4600mg, 4800mg, 5000mg, 5200mg, 5400mg, 5600mg, 5800mg, 6000mg, 6200mg, 6400mg, 6600mg, 6800mg, 7000mg, 7200mg, 7400mg, 7600mg, 7800mg, 8000mg, 8200mg, 8400mg, 8600mg, 8800mg, 9000mg, 9200mg, 9400mg, 9600mg, 9800mg, 10000mg	tablet, short acting injection, long acting injection
	Clopixol, Clopixon Acuphase, Clopixon Depot	tablet, intermediate acting and long acting injection*

\* Long acting injections are used for chronic psychoses only.





## References

1. Hilmer S, Gnjidic D. Rethinking psychotropics in nursing homes. *Med J Aust* 2013;198:77.
2. Westbury JL, Jackson S, Peterson GM. Psycholeptic use in aged care homes in Tasmania, Australia. *J Clin Pharm Ther* 2010;35:189-93.
3. Snowdon J, Galanos D, Vaswani D. Patterns of psychotropic medication use in nursing homes: surveys in Sydney, allowing comparisons over time and between countries. *Int psychogeriatr* 2011;23:1520-5.
4. AMH drug choice companion: aged care. Third ed. Adelaide: Australian Medicines Handbook Ltd, 2010.
5. Schneider L, Dagerman M, Insel P. Efficacy and adverse effects of atypical antipsychotics for dementia: meta analysis of randomised, placebo controlled trials. *Am J Geriatr Psychiatry* 2006;14:191-210.
6. US FDA. Information for Healthcare Professionals: Conventional Antipsychotics. 2008.
7. Practice Guideline 10: Antipsychotic medications as a treatment of behavioural and psychological symptoms of dementia. The Royal Australian and New Zealand College of Psychiatrists, 2009.
8. Therapeutic guidelines: psychotropic. 6th ed. Melbourne: Therapeutic Guidelines Ltd, 2008.
9. Accreditation essentials: Results and processes guide. Aged Care Standards and Accreditation Agency, 2009.
10. Snowdon J, Galanos D, Vaswani D. A 2009 Survey of psychotropic medication use in Sydney nursing homes. *Med J Aust* 2011;194:270-1.
11. Medical care of older persons in residential age care facilities. Melbourne: Royal Australian College of General Practitioners, 2006.
- 12.